Riluzolo (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Riluzolo" in Italian language version.

refsWebsite

Global rank Italian rank

34nih.gov

4^th place

9^th place

23oadoi.org

799^th place

22^nd place

23doi.org

2^nd place

7^th place

1torrinomedica.it

low place

2,002^nd place

1asrim.ch

low place

asrim.ch

Riluzolo, su asrim.ch. URL consultato l'8 luglio 2010.

doi.org

dx.doi.org

M. Graf, D. Ecker; R. Horowski; B. Kramer; P. Riederer; M. Gerlach; C. Hager; AC. Ludolph; G. Becker; J. Osterhage; WH. Jost, High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study., in J Neural Transm, vol. 112, n. 5, maggio 2005, pp. 649-60, DOI:10.1007/s00702-004-0220-1, PMID 15517433.
G. Bensimon, A. Ludolph; Y. Agid; M. Vidailhet; C. Payan; PN. Leigh; PN. Leigh; G. Bensimon; AC. Ludolph; PN. Leigh; Y. Agid, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study., in Brain, vol. 132, Pt 1, gennaio 2009, pp. 156-71, DOI:10.1093/brain/awn291, PMID 19029129.
PA. LeWitt, DC. Taylor, Protection against Parkinson's disease progression: clinical experience., in Neurotherapeutics, vol. 5, n. 2, aprile 2008, pp. 210-25, DOI:10.1016/j.nurt.2008.01.007, PMID 18394564.
C. Scherfler, T. Sather; E. Diguet; N. Stefanova; Z. Puschban; F. Tison; W. Poewe; GK. Wenning, Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)., in J Neural Transm, vol. 112, n. 8, agosto 2005, pp. 1025-33, DOI:10.1007/s00702-004-0245-5, PMID 15583958.
G. Ristori, S. Romano; A. Visconti; S. Cannoni; M. Spadaro; M. Frontali; FE. Pontieri; N. Vanacore; M. Salvetti, Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial., in Neurology, vol. 74, n. 10, marzo 2010, pp. 839-45, DOI:10.1212/WNL.0b013e3181d31e23, PMID 20211908.
VG. Shakkottai, CH. Chou; S. Oddo; CA. Sailer; HG. Knaus; GA. Gutman; ME. Barish; FM. LaFerla; KG. Chandy, Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia., in J Clin Invest, vol. 113, n. 4, febbraio 2004, pp. 582-90, DOI:10.1172/JCI20216, PMID 14966567.
N. Stefanova, P. Bücke; S. Duerr; GK. Wenning, Multiple system atrophy: an update., in Lancet Neurol, vol. 8, n. 12, dicembre 2009, pp. 1172-8, DOI:10.1016/S1474-4422(09)70288-1, PMID 19909915.
RC. Shelton, O. Osuntokun; AN. Heinloth; SA. Corya, Therapeutic options for treatment-resistant depression., in CNS Drugs, vol. 24, n. 2, febbraio 2010, pp. 131-61, DOI:10.2165/11530280-000000000-00000, PMID 20088620.
BP. Brennan, JI. Hudson; JE. Jensen; J. McCarthy; JL. Roberts; AP. Prescot; BM. Cohen; HG. Pope; PF. Renshaw; D. Ongür, Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole., in Neuropsychopharmacology, vol. 35, n. 3, febbraio 2010, pp. 834-46, DOI:10.1038/npp.2009.191, PMID 19956089.
G. Sanacora, Do glutamatergic agents represent a new class of antidepressant drugs? Part 1., in J Clin Psychiatry, vol. 70, n. 10, ottobre 2009, pp. 1473-5, DOI:10.4088/JCP.09ac05680blu, PMID 19906350.
R. Machado-Vieira, HK. Manji; CA. Zarate, The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders., in Neuroscientist, vol. 15, n. 5, ottobre 2009, pp. 525-39, DOI:10.1177/1073858409336093, PMID 19471044.
SJ. Mathew, JW. Murrough; M. aan het Rot; KA. Collins; DL. Reich; DS. Charney, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial., in Int J Neuropsychopharmacol, vol. 13, n. 1, febbraio 2010, pp. 71-82, DOI:10.1017/S1461145709000169, PMID 19288975.
SJ. Mathew, HK. Manji; DS. Charney, Novel drugs and therapeutic targets for severe mood disorders., in Neuropsychopharmacology, vol. 33, n. 9, agosto 2008, pp. 2080-92, DOI:10.1038/sj.npp.1301652, PMID 18172433.
G. Sanacora, SF. Kendell; Y. Levin; AA. Simen; LR. Fenton; V. Coric; JH. Krystal, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms., in Biol Psychiatry, vol. 61, n. 6, marzo 2007, pp. 822-5, DOI:10.1016/j.biopsych.2006.08.037, PMID 17141740.
H. Frieling, T. Hillemacher; JH. Demling; J. Kornhuber; S. Bleich, [New options in the treatment of depression], in Fortschr Neurol Psychiatr, vol. 75, n. 11, novembre 2007, pp. 641-52, DOI:10.1055/s-2007-959181, PMID 17366379.
T. Mestre, J. Ferreira; MM. Coelho; M. Rosa; C. Sampaio, Therapeutic interventions for disease progression in Huntington's disease., in Cochrane Database Syst Rev, n. 3, 2009, pp. CD006455, DOI:10.1002/14651858.CD006455.pub2, PMID 19588392.
F. Squitieri, A. Ciammola; C. Colonnese; A. Ciarmiello, Neuroprotective effects of riluzole in Huntington's disease., in Eur J Nucl Med Mol Imaging, vol. 35, n. 1, gennaio 2008, pp. 221-2, DOI:10.1007/s00259-007-0615-y, PMID 17987289.
GB. Landwehrmeyer, B. Dubois; JG. de Yébenes; B. Kremer; W. Gaus; PH. Kraus; H. Przuntek; M. Dib; A. Doble; W. Fischer; AC. Ludolph, Riluzole in Huntington's disease: a 3-year, randomized controlled study., in Ann Neurol, vol. 62, n. 3, settembre 2007, pp. 262-72, DOI:10.1002/ana.21181, PMID 17702031.
RM. Bonelli, P. Hofmann, A systematic review of the treatment studies in Huntington's disease since 1990., in Expert Opin Pharmacother, vol. 8, n. 2, febbraio 2007, pp. 141-53, DOI:10.1517/14656566.8.2.141, PMID 17257085.
V. Heiser, S. Engemann; W. Bröcker; I. Dunkel; A. Boeddrich; S. Waelter; E. Nordhoff; R. Lurz; N. Schugardt; S. Rautenberg; C. Herhaus, Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay., in Proc Natl Acad Sci U S A, 99 Suppl 4, dicembre 2002, pp. 16400-6, DOI:10.1073/pnas.182426599, PMID 12200548.
ZH. Qin, J. Wang; ZL. Gu, Development of novel therapies for Huntington's disease: hope and challenge., in Acta Pharmacol Sin, vol. 26, n. 2, febbraio 2005, pp. 129-42, DOI:10.1111/j.1745-7254.2005.00520.x, PMID 15663888.
DA. Ciraulo, O. Sarid-Segal; CM. Knapp; AM. Ciraulo; J. LoCastro; DA. Bloch; MA. Montgomery; DB. Leiderman; A. Elkashef, Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence., in Addiction, 100 Suppl 1, marzo 2005, pp. 12-22, DOI:10.1111/j.1360-0443.2005.00985.x, PMID 15730346.
M. Irifune, N. Kikuchi; T. Saida; T. Takarada; Y. Shimizu; C. Endo; K. Morita; T. Dohi; T. Sato; M. Kawahara, Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice., in Anesth Analg, vol. 104, n. 6, giugno 2007, pp. 1415-21, table of contents, DOI:10.1213/01.ane.0000263267.04198.36, PMID 17513634.

nih.gov

ncbi.nlm.nih.gov

Arun P, Moffett JR, Namboodiri AM., Riluzole decreases synthesis of N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells., in Brain Res., 12 aprile 2010 Apr 12, PMID 20394738.
Zoccolella S, Santamato A, Lamberti P., Current and emerging treatments for amyotrophic lateral sclerosis., in Neuropsychiatr Dis Treat., vol. 5, 16 novembre 2009, pp. 577-95, PMID 19966906.
M. Graf, D. Ecker; R. Horowski; B. Kramer; P. Riederer; M. Gerlach; C. Hager; AC. Ludolph; G. Becker; J. Osterhage; WH. Jost, High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study., in J Neural Transm, vol. 112, n. 5, maggio 2005, pp. 649-60, DOI:10.1007/s00702-004-0220-1, PMID 15517433.
G. Bensimon, A. Ludolph; Y. Agid; M. Vidailhet; C. Payan; PN. Leigh; PN. Leigh; G. Bensimon; AC. Ludolph; PN. Leigh; Y. Agid, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study., in Brain, vol. 132, Pt 1, gennaio 2009, pp. 156-71, DOI:10.1093/brain/awn291, PMID 19029129.
PA. LeWitt, DC. Taylor, Protection against Parkinson's disease progression: clinical experience., in Neurotherapeutics, vol. 5, n. 2, aprile 2008, pp. 210-25, DOI:10.1016/j.nurt.2008.01.007, PMID 18394564.
C. Scherfler, T. Sather; E. Diguet; N. Stefanova; Z. Puschban; F. Tison; W. Poewe; GK. Wenning, Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)., in J Neural Transm, vol. 112, n. 8, agosto 2005, pp. 1025-33, DOI:10.1007/s00702-004-0245-5, PMID 15583958.
PA. LeWitt, Clinical trials of neuroprotection for Parkinson's disease., in Neurology, vol. 63, 7 Suppl 2, ottobre 2004, pp. S23-31, PMID 15477583.
CA. Braz, V. Borges; HB. Ferraz, Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study., in Clin Neuropharmacol, vol. 27, n. 1, pp. 25-9, PMID 15090933.
G. Ristori, S. Romano; A. Visconti; S. Cannoni; M. Spadaro; M. Frontali; FE. Pontieri; N. Vanacore; M. Salvetti, Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial., in Neurology, vol. 74, n. 10, marzo 2010, pp. 839-45, DOI:10.1212/WNL.0b013e3181d31e23, PMID 20211908.
VG. Shakkottai, CH. Chou; S. Oddo; CA. Sailer; HG. Knaus; GA. Gutman; ME. Barish; FM. LaFerla; KG. Chandy, Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia., in J Clin Invest, vol. 113, n. 4, febbraio 2004, pp. 582-90, DOI:10.1172/JCI20216, PMID 14966567.
N. Stefanova, P. Bücke; S. Duerr; GK. Wenning, Multiple system atrophy: an update., in Lancet Neurol, vol. 8, n. 12, dicembre 2009, pp. 1172-8, DOI:10.1016/S1474-4422(09)70288-1, PMID 19909915.
RC. Shelton, O. Osuntokun; AN. Heinloth; SA. Corya, Therapeutic options for treatment-resistant depression., in CNS Drugs, vol. 24, n. 2, febbraio 2010, pp. 131-61, DOI:10.2165/11530280-000000000-00000, PMID 20088620.
BP. Brennan, JI. Hudson; JE. Jensen; J. McCarthy; JL. Roberts; AP. Prescot; BM. Cohen; HG. Pope; PF. Renshaw; D. Ongür, Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole., in Neuropsychopharmacology, vol. 35, n. 3, febbraio 2010, pp. 834-46, DOI:10.1038/npp.2009.191, PMID 19956089.
G. Sanacora, Do glutamatergic agents represent a new class of antidepressant drugs? Part 1., in J Clin Psychiatry, vol. 70, n. 10, ottobre 2009, pp. 1473-5, DOI:10.4088/JCP.09ac05680blu, PMID 19906350.
R. Machado-Vieira, HK. Manji; CA. Zarate, The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders., in Neuroscientist, vol. 15, n. 5, ottobre 2009, pp. 525-39, DOI:10.1177/1073858409336093, PMID 19471044.
SJ. Mathew, JW. Murrough; M. aan het Rot; KA. Collins; DL. Reich; DS. Charney, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial., in Int J Neuropsychopharmacol, vol. 13, n. 1, febbraio 2010, pp. 71-82, DOI:10.1017/S1461145709000169, PMID 19288975.
SJ. Mathew, HK. Manji; DS. Charney, Novel drugs and therapeutic targets for severe mood disorders., in Neuropsychopharmacology, vol. 33, n. 9, agosto 2008, pp. 2080-92, DOI:10.1038/sj.npp.1301652, PMID 18172433.
G. Sanacora, SF. Kendell; Y. Levin; AA. Simen; LR. Fenton; V. Coric; JH. Krystal, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms., in Biol Psychiatry, vol. 61, n. 6, marzo 2007, pp. 822-5, DOI:10.1016/j.biopsych.2006.08.037, PMID 17141740.
H. Frieling, T. Hillemacher; JH. Demling; J. Kornhuber; S. Bleich, [New options in the treatment of depression], in Fortschr Neurol Psychiatr, vol. 75, n. 11, novembre 2007, pp. 641-52, DOI:10.1055/s-2007-959181, PMID 17366379.
T. Mestre, J. Ferreira; MM. Coelho; M. Rosa; C. Sampaio, Therapeutic interventions for disease progression in Huntington's disease., in Cochrane Database Syst Rev, n. 3, 2009, pp. CD006455, DOI:10.1002/14651858.CD006455.pub2, PMID 19588392.
F. Squitieri, A. Ciammola; C. Colonnese; A. Ciarmiello, Neuroprotective effects of riluzole in Huntington's disease., in Eur J Nucl Med Mol Imaging, vol. 35, n. 1, gennaio 2008, pp. 221-2, DOI:10.1007/s00259-007-0615-y, PMID 17987289.
GB. Landwehrmeyer, B. Dubois; JG. de Yébenes; B. Kremer; W. Gaus; PH. Kraus; H. Przuntek; M. Dib; A. Doble; W. Fischer; AC. Ludolph, Riluzole in Huntington's disease: a 3-year, randomized controlled study., in Ann Neurol, vol. 62, n. 3, settembre 2007, pp. 262-72, DOI:10.1002/ana.21181, PMID 17702031.
RM. Bonelli, P. Hofmann, A systematic review of the treatment studies in Huntington's disease since 1990., in Expert Opin Pharmacother, vol. 8, n. 2, febbraio 2007, pp. 141-53, DOI:10.1517/14656566.8.2.141, PMID 17257085.
V. Heiser, S. Engemann; W. Bröcker; I. Dunkel; A. Boeddrich; S. Waelter; E. Nordhoff; R. Lurz; N. Schugardt; S. Rautenberg; C. Herhaus, Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay., in Proc Natl Acad Sci U S A, 99 Suppl 4, dicembre 2002, pp. 16400-6, DOI:10.1073/pnas.182426599, PMID 12200548.
C. Cepeda, RS. Hurst; CR. Calvert; E. Hernández-Echeagaray; OK. Nguyen; E. Jocoy; LJ. Christian; MA. Ariano; MS. Levine, Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease., in J Neurosci, vol. 23, n. 3, febbraio 2003, pp. 961-9, PMID 12574425.
ZH. Qin, J. Wang; ZL. Gu, Development of novel therapies for Huntington's disease: hope and challenge., in Acta Pharmacol Sin, vol. 26, n. 2, febbraio 2005, pp. 129-42, DOI:10.1111/j.1745-7254.2005.00520.x, PMID 15663888.
RA. Pagon, TC. Bird; CR. Dolan; K. Stephens; S. Donkervoort; T. Siddique, Amyotrophic Lateral Sclerosis Overview, PMID 20301623.
DA. Ciraulo, O. Sarid-Segal; CM. Knapp; AM. Ciraulo; J. LoCastro; DA. Bloch; MA. Montgomery; DB. Leiderman; A. Elkashef, Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence., in Addiction, 100 Suppl 1, marzo 2005, pp. 12-22, DOI:10.1111/j.1360-0443.2005.00985.x, PMID 15730346.
Y. Itzhak, JL. Martin, Effect of riluzole and gabapentin on cocaine- and methamphetamine-induced behavioral sensitization in mice., in Psychopharmacology (Berl), vol. 151, n. 2-3, agosto 2000, pp. 226-33, PMID 10972469.
RL. Brackett, B. Pouw; JF. Blyden; M. Nour; RR. Matsumoto, Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex., in Neuropharmacology, vol. 39, n. 3, gennaio 2000, pp. 407-18, PMID 10698007.
M. Irifune, N. Kikuchi; T. Saida; T. Takarada; Y. Shimizu; C. Endo; K. Morita; T. Dohi; T. Sato; M. Kawahara, Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice., in Anesth Analg, vol. 104, n. 6, giugno 2007, pp. 1415-21, table of contents, DOI:10.1213/01.ane.0000263267.04198.36, PMID 17513634.
B. Sung, G. Lim; J. Mao, Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats., in J Neurosci, vol. 23, n. 7, aprile 2003, pp. 2899-910, PMID 12684477.
J. Mao, B. Sung; RR. Ji; G. Lim, Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity., in J Neurosci, vol. 22, n. 18, settembre 2002, pp. 8312-23, PMID 12223586.
NA. Hammer, J. Lillesø; JL. Pedersen; H. Kehlet, Effect of riluzole on acute pain and hyperalgesia in humans., in Br J Anaesth, vol. 82, n. 5, maggio 1999, pp. 718-22, PMID 10536550.

oadoi.org

M. Graf, D. Ecker; R. Horowski; B. Kramer; P. Riederer; M. Gerlach; C. Hager; AC. Ludolph; G. Becker; J. Osterhage; WH. Jost, High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study., in J Neural Transm, vol. 112, n. 5, maggio 2005, pp. 649-60, DOI:10.1007/s00702-004-0220-1, PMID 15517433.
G. Bensimon, A. Ludolph; Y. Agid; M. Vidailhet; C. Payan; PN. Leigh; PN. Leigh; G. Bensimon; AC. Ludolph; PN. Leigh; Y. Agid, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study., in Brain, vol. 132, Pt 1, gennaio 2009, pp. 156-71, DOI:10.1093/brain/awn291, PMID 19029129.
PA. LeWitt, DC. Taylor, Protection against Parkinson's disease progression: clinical experience., in Neurotherapeutics, vol. 5, n. 2, aprile 2008, pp. 210-25, DOI:10.1016/j.nurt.2008.01.007, PMID 18394564.
C. Scherfler, T. Sather; E. Diguet; N. Stefanova; Z. Puschban; F. Tison; W. Poewe; GK. Wenning, Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)., in J Neural Transm, vol. 112, n. 8, agosto 2005, pp. 1025-33, DOI:10.1007/s00702-004-0245-5, PMID 15583958.
G. Ristori, S. Romano; A. Visconti; S. Cannoni; M. Spadaro; M. Frontali; FE. Pontieri; N. Vanacore; M. Salvetti, Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial., in Neurology, vol. 74, n. 10, marzo 2010, pp. 839-45, DOI:10.1212/WNL.0b013e3181d31e23, PMID 20211908.
VG. Shakkottai, CH. Chou; S. Oddo; CA. Sailer; HG. Knaus; GA. Gutman; ME. Barish; FM. LaFerla; KG. Chandy, Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia., in J Clin Invest, vol. 113, n. 4, febbraio 2004, pp. 582-90, DOI:10.1172/JCI20216, PMID 14966567.
N. Stefanova, P. Bücke; S. Duerr; GK. Wenning, Multiple system atrophy: an update., in Lancet Neurol, vol. 8, n. 12, dicembre 2009, pp. 1172-8, DOI:10.1016/S1474-4422(09)70288-1, PMID 19909915.
RC. Shelton, O. Osuntokun; AN. Heinloth; SA. Corya, Therapeutic options for treatment-resistant depression., in CNS Drugs, vol. 24, n. 2, febbraio 2010, pp. 131-61, DOI:10.2165/11530280-000000000-00000, PMID 20088620.
BP. Brennan, JI. Hudson; JE. Jensen; J. McCarthy; JL. Roberts; AP. Prescot; BM. Cohen; HG. Pope; PF. Renshaw; D. Ongür, Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole., in Neuropsychopharmacology, vol. 35, n. 3, febbraio 2010, pp. 834-46, DOI:10.1038/npp.2009.191, PMID 19956089.
G. Sanacora, Do glutamatergic agents represent a new class of antidepressant drugs? Part 1., in J Clin Psychiatry, vol. 70, n. 10, ottobre 2009, pp. 1473-5, DOI:10.4088/JCP.09ac05680blu, PMID 19906350.
R. Machado-Vieira, HK. Manji; CA. Zarate, The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders., in Neuroscientist, vol. 15, n. 5, ottobre 2009, pp. 525-39, DOI:10.1177/1073858409336093, PMID 19471044.
SJ. Mathew, JW. Murrough; M. aan het Rot; KA. Collins; DL. Reich; DS. Charney, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial., in Int J Neuropsychopharmacol, vol. 13, n. 1, febbraio 2010, pp. 71-82, DOI:10.1017/S1461145709000169, PMID 19288975.
SJ. Mathew, HK. Manji; DS. Charney, Novel drugs and therapeutic targets for severe mood disorders., in Neuropsychopharmacology, vol. 33, n. 9, agosto 2008, pp. 2080-92, DOI:10.1038/sj.npp.1301652, PMID 18172433.
G. Sanacora, SF. Kendell; Y. Levin; AA. Simen; LR. Fenton; V. Coric; JH. Krystal, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms., in Biol Psychiatry, vol. 61, n. 6, marzo 2007, pp. 822-5, DOI:10.1016/j.biopsych.2006.08.037, PMID 17141740.
H. Frieling, T. Hillemacher; JH. Demling; J. Kornhuber; S. Bleich, [New options in the treatment of depression], in Fortschr Neurol Psychiatr, vol. 75, n. 11, novembre 2007, pp. 641-52, DOI:10.1055/s-2007-959181, PMID 17366379.
T. Mestre, J. Ferreira; MM. Coelho; M. Rosa; C. Sampaio, Therapeutic interventions for disease progression in Huntington's disease., in Cochrane Database Syst Rev, n. 3, 2009, pp. CD006455, DOI:10.1002/14651858.CD006455.pub2, PMID 19588392.
F. Squitieri, A. Ciammola; C. Colonnese; A. Ciarmiello, Neuroprotective effects of riluzole in Huntington's disease., in Eur J Nucl Med Mol Imaging, vol. 35, n. 1, gennaio 2008, pp. 221-2, DOI:10.1007/s00259-007-0615-y, PMID 17987289.
GB. Landwehrmeyer, B. Dubois; JG. de Yébenes; B. Kremer; W. Gaus; PH. Kraus; H. Przuntek; M. Dib; A. Doble; W. Fischer; AC. Ludolph, Riluzole in Huntington's disease: a 3-year, randomized controlled study., in Ann Neurol, vol. 62, n. 3, settembre 2007, pp. 262-72, DOI:10.1002/ana.21181, PMID 17702031.
RM. Bonelli, P. Hofmann, A systematic review of the treatment studies in Huntington's disease since 1990., in Expert Opin Pharmacother, vol. 8, n. 2, febbraio 2007, pp. 141-53, DOI:10.1517/14656566.8.2.141, PMID 17257085.
V. Heiser, S. Engemann; W. Bröcker; I. Dunkel; A. Boeddrich; S. Waelter; E. Nordhoff; R. Lurz; N. Schugardt; S. Rautenberg; C. Herhaus, Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay., in Proc Natl Acad Sci U S A, 99 Suppl 4, dicembre 2002, pp. 16400-6, DOI:10.1073/pnas.182426599, PMID 12200548.
ZH. Qin, J. Wang; ZL. Gu, Development of novel therapies for Huntington's disease: hope and challenge., in Acta Pharmacol Sin, vol. 26, n. 2, febbraio 2005, pp. 129-42, DOI:10.1111/j.1745-7254.2005.00520.x, PMID 15663888.
DA. Ciraulo, O. Sarid-Segal; CM. Knapp; AM. Ciraulo; J. LoCastro; DA. Bloch; MA. Montgomery; DB. Leiderman; A. Elkashef, Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence., in Addiction, 100 Suppl 1, marzo 2005, pp. 12-22, DOI:10.1111/j.1360-0443.2005.00985.x, PMID 15730346.
M. Irifune, N. Kikuchi; T. Saida; T. Takarada; Y. Shimizu; C. Endo; K. Morita; T. Dohi; T. Sato; M. Kawahara, Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice., in Anesth Analg, vol. 104, n. 6, giugno 2007, pp. 1415-21, table of contents, DOI:10.1213/01.ane.0000263267.04198.36, PMID 17513634.

torrinomedica.it

RILUTEK. RCP, su torrinomedica.it. URL consultato l'8 luglio 2010.